CareDx Future Growth

Future criteria checks 4/6

CareDx is forecast to grow earnings and revenue by 95% and 12.3% per annum respectively while EPS is expected to grow by 95.5% per annum.

Key information

95.0%

Earnings growth rate

95.5%

EPS growth rate

Biotechs earnings growth28.3%
Revenue growth rate12.3%
Future return on equityn/a
Analyst coverage

Good

Last updated06 Nov 2024

Recent future growth updates

Recent updates

The Market Doesn't Like What It Sees From CareDx, Inc's (NASDAQ:CDNA) Revenues Yet As Shares Tumble 26%

Nov 05
The Market Doesn't Like What It Sees From CareDx, Inc's (NASDAQ:CDNA) Revenues Yet As Shares Tumble 26%

CareDx Resolves Key Issues: Poised For Growth In Transplant Diagnostics

Sep 29

CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 34% But Its Business Prospects Need A Lift Too

Aug 01
CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 34% But Its Business Prospects Need A Lift Too

CareDx: Benefiting From Some Certainty

Jul 15

Why Investors Shouldn't Be Surprised By CareDx, Inc's (NASDAQ:CDNA) 28% Share Price Plunge

Apr 27
Why Investors Shouldn't Be Surprised By CareDx, Inc's (NASDAQ:CDNA) 28% Share Price Plunge

CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 40% But Its Business Prospects Need A Lift Too

Mar 02
CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 40% But Its Business Prospects Need A Lift Too

CareDx, Inc's (NASDAQ:CDNA) Shares Bounce 26% But Its Business Still Trails The Industry

Dec 27
CareDx, Inc's (NASDAQ:CDNA) Shares Bounce 26% But Its Business Still Trails The Industry

CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Dec 27
CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Benign Growth For CareDx, Inc (NASDAQ:CDNA) Underpins Its Share Price

Jun 29
Benign Growth For CareDx, Inc (NASDAQ:CDNA) Underpins Its Share Price

Analyst Forecasts Just Became More Bearish On CareDx, Inc (NASDAQ:CDNA)

May 16
Analyst Forecasts Just Became More Bearish On CareDx, Inc (NASDAQ:CDNA)

CareDx: Shaking Off First-Mover Disadvantage

Oct 18

CareDx: Best Near Cap-Gain Health Diagnostics Prospect Say Market Makers

Aug 08

Earnings and Revenue Growth Forecasts

NasdaqGM:CDNA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20264142N/A796
12/31/2025363-25N/A418
12/31/2024328-36N/A308
9/30/2024313-14418N/A
6/30/2024297-160-22-15N/A
3/31/2024275-183-42-34N/A
12/31/2023280-190-28-18N/A
9/30/2023297-91-14-3N/A
6/30/2023309-84-140N/A
3/31/2023320-81-22-3N/A
12/31/2022322-77-50-25N/A
9/30/2022319-74-55-28N/A
6/30/2022315-69-45-21N/A
3/31/2022308-50-34-7N/A
12/31/2021296-31-40-19N/A
9/30/2021276-18-31-16N/A
6/30/2021254-9-27-11N/A
3/31/2021221-14-83N/A
12/31/2020192-192333N/A
9/30/2020169-201425N/A
6/30/2020150-191321N/A
3/31/2020139-20-40N/A
12/31/2019127-22-6-3N/A
9/30/2019115-21-30N/A
6/30/2019102-39-30N/A
3/31/201988-45-13-5N/A
12/31/201877-47-11-4N/A
9/30/201866-75-15-8N/A
6/30/201857-69N/A-11N/A
3/31/201851-59N/A-12N/A
12/31/201748-55N/A-14N/A
9/30/201747-39N/A-15N/A
6/30/201747-29N/A-14N/A
3/31/201746-35N/A-17N/A
12/31/201641-39N/A-17N/A
9/30/201636-29N/A-17N/A
6/30/201631-28N/A-19N/A
3/31/201627-21N/A-15N/A
12/31/201528-14N/A-10N/A
9/30/201529-9N/A-6N/A
6/30/201529-4N/A-7N/A
3/31/2015290N/A-5N/A
12/31/2014271N/A-3N/A
9/30/2014250N/A-4N/A
6/30/201424-2N/A2N/A
3/31/201423-3N/A1N/A
12/31/201322-4N/A-1N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CDNA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: CDNA is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CDNA is expected to become profitable in the next 3 years.

Revenue vs Market: CDNA's revenue (12.3% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: CDNA's revenue (12.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CDNA's Return on Equity is forecast to be high in 3 years time


Discover growth companies